We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Mesenchymal Stem Cell Transplantation in Osteoarthritis of Hip Joint

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01499056
Recruitment Status : Completed
First Posted : December 26, 2011
Last Update Posted : December 26, 2011
Information provided by (Responsible Party):
Royan Institute

December 17, 2011
December 26, 2011
December 26, 2011
June 2010
February 2011   (Final data collection date for primary outcome measure)
  • swelling of hip joint [ Time Frame: 2 months ]
    Evaluatin the swelling of hip joint by physical examination after intra articular injection.
  • deterioration of joint function [ Time Frame: 2 months ]
    Evaluation deterioration of joint function by physical examination after intra articular cell injection.
  • skin allergic reaction [ Time Frame: 1 week ]
    Evaluation the skin allergic reaction like erythema,rash,swelling after intra articular cell injection.
  • Respiratory reaction [ Time Frame: 1 week ]
    Evaluation the Respiratory reaction like dyspenea by physical examination after imtra articular cell injection.
Same as current
No Changes Posted
  • Quantitative changes in pain intensity [ Time Frame: 2 months ]
    Evaluation Quantitative changes in pain intensity measured by Visual Analogue Scale after intra articular cell injection 2 months after cell transplantation in compare with base line (before injection)
  • physical function improvement [ Time Frame: 2 months ]
    Evaluation the physical function improvement Measured by WOMAC osteoarthritis index and Harris Hip Score.
  • subchondral bone edema [ Time Frame: 2 months ]
    Evaluation the subchondral bone edema by MRI
  • cartilage thickness [ Time Frame: 2 months ]
    measuring the cartilage thickness after cell transplantation by MRI
Same as current
Not Provided
Not Provided
Mesenchymal Stem Cell Transplantation in Osteoarthritis of Hip Joint
Evaluation the Side Effect of Bone Marrow Derived Mesenchymal Stem Cell in Patients With Osteoarthritis of Hip Joint
Osteoarthritis of the hip is a common type of osteoarthritis which can cause significant problems. First-line of management for patient with osteoarthritis consists of weight reduction, education, and analgesic medication. If necessary, invasive treatment like total hip replacement are performed for the patient. The objective of this study was to assess the safety of bone marrow mesenchymal stem cells (BM-MSCs) implantation in patients with hip osteoarthritis
This is a phase one clinical study designed to investigate the safety of intra-articular injection of cultured autologous BM-MSCs in patients with severe hip osteoarthritis candidate for total hip replacement. All subjects will undergo bone marrow aspiration. Autologous MSCs will be extracted and cultured for 4 weeks. Patients will receive intra-articular injection of cultured MSCs under the guide of fluoroscopy. Paraclinical studies (X-Ray and MRI) will be done before and 6 months after treatment. Pain relief and functional improvement of the joint will be assessed by VAS, WOMAC, and Harris Hip Score questionnaire before treatment, and 2 and 6 months after treatment.
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Hip Osteoarthritis
Biological: stem cell injection
intra articular inection of mesenchymal stem cell
Experimental: hip osteoarthritis
The patients with hip joint osteoarthritis who underwent cell injection
Intervention: Biological: stem cell injection
Emadedin M, Ghorbani Liastani M, Fazeli R, Mohseni F, Moghadasali R, Mardpour S, Hosseini SE, Niknejadi M, Moeininia F, Aghahossein Fanni A, Baghban Eslaminejhad R, Vosough Dizaji A, Labibzadeh N, Mirazimi Bafghi A, Baharvand H, Aghdami N. Long-Term Follow-up of Intra-articular Injection of Autologous Mesenchymal Stem Cells in Patients with Knee, Ankle, or Hip Osteoarthritis. Arch Iran Med. 2015 Jun;18(6):336-44. doi: 015186/AIM.003.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
March 2011
February 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Osteoarthritis diagnosed by MRI
  • End stage osteoarthritis candidate for total hip replacement

Exclusion Criteria:

  • Pregnancy or lactating
  • Positive tests for HIV, HCV, HBV
  • Active neurologic disorder
  • End organ damage
  • Uncontrolled endocrine disorder
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Iran, Islamic Republic of
Not Provided
Not Provided
Royan Institute
Royan Institute
Not Provided
Study Chair: Hamid Gourabi, PhD Head of Royan Institute
Study Director: Nasser Aghdami, MD,PhD Head of Royan Cell therapy Center
Principal Investigator: Mohsen Emadeddin, MD scientist
Royan Institute
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP